Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix, BioRealm, RUCDR Ally to Genotype NIDA Biobank

NEW YORK (GenomeWeb) – Affymetrix, BioRealm, and RUCDR Infinite Biologics today announced a strategic alliance to genotype the National Institute of Drug Abuse biorepository.

The samples will be genotyped using the BioRealm SmokeScreen array, a genome-wide array that looks at more than 1,000 addiction-related genes and which was developed in conjunction with NIDA's Genetics Consortium and Affymetrix.

"Because of the SmokeScreen array, we have the ability to reveal genetic information previously hidden in NIDA's samples," RUCDR COO Andrew Brooks said in a statement. "It is a validated platform that will become a crucial tool in advancing addiction research and moving the field towards personalized treatment."

The NIDA biobank contains more than 50,000 samples collected from human subjects in agency-funded research, and is maintained at Rutgers University by RUCDR, a unit of the school's Human Genetics Institute of New Jersey. In May of 2014, RUCDR received at $19 million grant to expand the services it provides to NIDA scientists.

The Scan

Less Than Half

An effort to reproduce key findings from high-profile preclinical cancer studies finds less than half could be replicated, according to the Scientist.

Still Some SARS-CoV-2 Sequencing Holes

The Wall Street Journal reports that viral genomic surveillance has improved in the US, though says there are still gaps.

Avoiding Passing Them On

People with known disease-linked genetic variants are turning to in vitro fertilization so as to not pass those variants to their children, the Washington Post says.

PNAS Papers on Long Cell-Free DNA in Maternal Plasma, Genetic Propensity for Voting

In PNAS this week: long, cell-free DNA of maternal and fetal origins identified in maternal plasma, and more.